Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Setmelanotide for Genetic Obesity
NCT03651765Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Jan 2025
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of setmelanotide in obesity, sponsored by Rhythm Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events up to 5.6 years. Started Jul 2018; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03651765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651765.